Agenus Inc (AGEN) Stock Price, Quote & News

Company Profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 674 4400

Fax: 781 674 4200

Website: www.agenusbio.com

Address:

3 Forbes Road, Lexington, United States

neversurrender2024 Jun. 25 at 2:07 PM

$AGEN look out below!

0 · Reply

neversurrender2024 Jun. 25 at 2:00 PM

$AGEN its almost a year ago the fda requested garo do a phase 3 clinical trial, watch this tumble when garos hail mary comes crashing down!

1 · Reply

neversurrender2024 Jun. 25 at 1:49 PM

$AGEN got atm ! garos dilution machine hard at work!

0 · Reply

Biotechguy21 Jun. 25 at 11:44 AM

$AGEN try harder 2 logs lower

0 · Reply

2_logs_higher Jun. 25 at 10:11 AM

$AGEN Saoniqx, QS-21 Stimulon sure hope the deal with ZYDUS better than the deal with GSK. https://www.gsk.com/en-gb/media/press-releases/japan-s-ministry-of-health-labour-and-welfare-accepts-regulatory-application-to-expand-use-of-gsk-s-rsv-vaccine-arexvy/ Sent from my iPhone

1 · Reply

2_logs_higher Jun. 25 at 10:03 AM

$AGEN Pages 32-34 in Zydus https://stockdiscovery.s3.amazonaws.com/insight/india/4331/Investor%20Presentation/IP-Jun25.pdf

1 · Reply

2_logs_higher Jun. 25 at 9:58 AM

$AGEN BOT+BAL are coming to change the world for immunotherapy-2025 https://youtube.com/shorts/WQ8xWUtaqII?si=TUan_uq0zei9x92Y

1 · Reply

Scooter0732 Jun. 24 at 3:22 PM

$AGEN https://www.youtube.com/watch?v=gp5JCrSXkJY

1 · Reply

2_logs_higher Jun. 24 at 11:53 AM

$AGEN BOT + BAL cited in "The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types" 111. Hissong, E. et al. Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient (pMMR) and deficient (dMMR) colorectal cancer (CRC): NEST clinical trial update. J. Clin. Oncol. 43, 207 (2025). 112. Ghelardi, F. et al. Preoperative botensilimab (BOT) with or without balstilimab (BAL) for patients with resectable locally advanced pMMR or dMMR colon cancer: results from the UNICORN trial by GONO. J. Clin. Oncol. 43, 158 (2025). https://www.nature.com/articles/s43018-025-00990-7

1 · Reply

2_logs_higher Jun. 24 at 11:47 AM

$AGEN will agen break thru the 200DMA?

1 · Reply

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

Jun 10, 2025, 1:30 PM EDT - 14 days ago

Agenus Announces Virtual Annual Shareholders Meeting

Jun 4, 2025, 2:38 PM EDT - 20 days ago

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang

Jun 3, 2025, 7:00 AM EDT - 22 days ago

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US

May 30, 2025, 7:30 AM EDT - 26 days ago

Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer

May 23, 2025, 3:09 PM EDT - 4 weeks ago

Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide

May 15, 2025, 10:40 AM EDT - 5 weeks ago

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

May 12, 2025, 2:46 PM EDT - 6 weeks ago

Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript

May 12, 2025, 7:30 AM EDT - 6 weeks ago

Agenus Reports Q1 2025 Financial Results and Key Business Updates

May 12, 2025, 7:20 AM EDT - 6 weeks ago

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

Apr 29, 2025, 7:30 AM EDT - 2 months ago

Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

Apr 28, 2025, 3:30 PM EDT - 2 months ago

Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

Apr 25, 2025, 1:05 PM EDT - 2 months ago

Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

Apr 23, 2025, 12:05 PM EDT - 2 months ago

Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

Mar 25, 2025, 4:40 PM EDT - 3 months ago

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

Mar 19, 2025, 7:30 AM EDT - 3 months ago

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

Mar 11, 2025, 10:39 AM EDT - 3 months ago

Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 7:30 AM EDT - 3 months ago

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

Feb 26, 2025, 4:48 PM EST - 4 months ago

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Feb 25, 2025, 2:30 PM EST - 4 months ago

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

Feb 25, 2025, 8:26 AM EST - 4 months ago

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Feb 24, 2025, 8:33 AM EST - 4 months ago

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

Feb 23, 2025, 7:38 PM EST - 4 months ago

CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 4 months ago

Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

$Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas$